Nearly 100% of the imports had a final destination of Indiana, according to U.S. customs ... Merck recently began construction on its first U.S. plant to make Keytruda. Lilly said earlier this year it ...

Eli Lilly launches Mounjaro KwikPen in India, expanding weight-loss drug options and intensifying competition with Novo Nordisk.

HealthDay News — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront.

Even with these potential headwinds, though, there are excellent reasons to invest in Eli Lilly. Let's consider three of them. Image source: Getty Images.

Eli Lilly and Company's recovery has not regained fervor as the digestion over its high-growth premium continues. Learn more about LLY stock here.

Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with ...

Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics marks a strategic expansion into cardiovascular genetic medicine. The pharmaceutical giant paid a premium of about 113% over Verve’s ...

President Trump will host on Wednesday top executives from companies including Nvidia, Johnson & Johnson, Eli Lilly, GE Aerospace and SoftBank, as promotes investment in the U.S., per the White ...

With detailed readouts from a suite of late-stage trials now on tap, Eli Lilly is heading to regulators in pursuit of a green light for its once-a-week insulin asset efsitora alfa.

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent implosion of Novo’s partnership with telehealth firm Hims & Hers suggests ...

Proponents of cultivated meat products say the new technology could make food systems more sustainable and save lives, but mass production is far out.

How should companies be thinking about investing resources toward AI capabilities? It’s no longer a question of whether to build their own capabilities or buy them. Instead, they are looking at ...